Related Experiment Videos
Treatment of DIC with antithrombin III concentrates
Bibliotheca Haematologica
|January 1, 1983
Insights
Antithrombin III (AT III) concentrates effectively treated 60% of patients with disseminated intravascular coagulation (DIC) unresponsive to heparin. This therapy enhanced heparin
Area of Science:
- Hematology
- Critical Care Medicine
Background:
- Disseminated intravascular coagulation (DIC) is a life-threatening condition characterized by widespread activation of coagulation.
- Heparin therapy is a standard treatment for DIC, but some patients do not respond adequately.
Observation:
- Twenty-one patients with DIC refractory to initial heparin treatment were studied.
- Antithrombin III (AT III) concentrates were administered to these patients.
Findings:
- Approximately 60% of patients showed effective treatment response following AT III concentrate administration.
- AT III concentrates enhanced the efficacy of concurrent heparin therapy.
- This approach reduced the need for excessive plasma transfusions, mitigating cardiovascular burden.
Implications:
- Antithrombin III concentrate administration represents a viable therapeutic option for heparin-resistant DIC.
- Optimizing AT III levels may improve outcomes in complex coagulopathies.
- Reducing plasma transfusion requirements can enhance patient safety and resource utilization.
Abstract:
We administered AT III concentrates to 21 patients with DIC who failed to respond initially to heparin therapy. About 60% of these 21 patients were effectively treated with AT III concentrates by enhancing the effect of heparin and alleviating the burden of excessive plasma transfusions on the cardiovascular system.